Overview

• The Trump administration's Justice Department filed a brief requesting the dismissal of a lawsuit by Missouri, Kansas, and Idaho challenging FDA rules on mifepristone access.
• The DOJ contends the states lack legal standing and that Texas is an improper venue for the case, echoing arguments made by the Biden administration earlier this year.
• The lawsuit targets FDA regulatory changes from 2016 and 2021 that expanded access to mifepristone, including telemedicine prescriptions and mail delivery.
• Last year, the Supreme Court dismissed a similar challenge by private anti-abortion groups, ruling they lacked standing to sue over FDA regulations.
• The Trump administration has avoided addressing the merits of the case, focusing instead on procedural issues like venue and statute of limitations.